Tinea incognito is the clinical term for a fungal skin infection whose appearance has been altered — and often worsened — by the application of a topical corticosteroid. It is one of the most common reasons for treatment failure in patients who present at the pharmacy counter with a persistent, unusual-looking rash.

How it happens

The typical sequence is straightforward. A patient develops a patch of ringworm (tinea corporis), psoriasis-like scaling, or an itchy red area they cannot identify. They reach for the most accessible anti-itch product: an over-the-counter hydrocortisone cream. The steroid suppresses the immune response that normally keeps the fungus contained, allowing the dermatophyte to spread while simultaneously reducing the characteristic raised, scaly border that makes ringworm recognisable.

The result is a rash that no longer looks like a textbook fungal infection. The well-defined ring disappears. The area may become larger, flatter, and more diffuse. Satellite lesions can appear. The patient returns to the pharmacy reporting that "the cream helped at first but now it's worse."

According to NICE Clinical Knowledge Summaries, topical corticosteroids should not be used on undiagnosed skin conditions, precisely because of this masking effect.

What pharmacy teams should look for

Tinea incognito can be difficult to identify because the classic ringworm signs are suppressed. Features that should raise suspicion include:

• A rash that initially improved with hydrocortisone but recurred or worsened when the cream was stopped
• An unusually widespread or poorly defined rash in an area where ringworm is common (trunk, groin, limbs)
• Loss of the typical annular (ring-shaped) border
• A history of prolonged or repeated topical steroid use on the affected area
• Follicular papules or pustules within the rash — steroids can drive the fungus into hair follicles, producing a condition called Majocchi granuloma

If a patient describes a rash that "keeps coming back" after steroid treatment, fungal infection modified by the steroid should be high on the differential list.

The pharmacy response

Step 1: Stop the steroid

The first action is to advise the patient to discontinue the topical corticosteroid on the affected area. This alone may allow the rash to revert to a more recognisable pattern over one to two weeks, though the infection will not resolve without antifungal treatment.

Step 2: Start a topical antifungal

For mild, localised tinea incognito, a topical antifungal is appropriate. According to the BNF, suitable options include:

Terbinafine is fungicidal rather than fungistatic and may clear infections faster, but clotrimazole and miconazole are equally effective for most superficial dermatophyte infections.

Step 3: Refer if needed

Referral to a GP is appropriate when:

• The rash is extensive (covering more than 10% of body surface area)
• The face, scalp, or nails are involved
• Follicular involvement or deep nodules suggest Majocchi granuloma
• The infection has not responded to two weeks of appropriate topical antifungal treatment
• The patient is immunocompromised

A GP may arrange skin scrapings for mycology to confirm the diagnosis, and oral antifungal therapy (typically terbinafine or itraconazole) may be required for deeper or more widespread infections.

Prevention: the pharmacy conversation

The most effective preventive measure is patient education at the point of sale. When selling hydrocortisone cream, pharmacy teams can include a brief caution: hydrocortisone should not be used on a rash that might be fungal. Key signs that suggest a fungal origin include a ring-shaped border, scaling, and involvement of warm, moist areas such as the groin, feet, or skin folds.

For patients who are uncertain about the nature of their rash, advising a GP consultation before starting any topical steroid is the safest course.

PharmSee's pharmacy services guide can help patients locate pharmacies offering skin condition consultations in their area.

Key points

• Tinea incognito is a fungal infection modified by topical steroid use, making it harder to diagnose
• The steroid suppresses inflammation but allows the fungus to spread
• Stopping the steroid and starting an appropriate topical antifungal is the first-line approach
• Refer to a GP for extensive, facial, follicular, or treatment-resistant cases
• Patient education at the hydrocortisone counter is the best prevention strategy

Sources: NICE CKS (Fungal skin infection — body and groin), BNF (Antifungals, topical), NHS (Ringworm). Article reflects guidance current as of April 2026.